// App-Quantinova.ai

9006 : Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

Researchers

Presenter

  • Joshua Bauml

Principal Investigators

  • Keunchil Park

  • Ki Hyeong Lee

  • EUN KYUNG CHO

  • Dong-Wan Kim

  • Sang-We Kim

  • Eric B. Haura

  • Joshua K. Sabari

  • Rachel E. Sanborn

  • Misako Nagasaka

  • Sai-Hong Ignatius Ou

  • Anna Rachel Minchom

  • Jorge E. Gomez

  • Joshua C. Curtin

  • Grace Gao

  • Amy Roshak

  • Meena Thayu

  • Roland Elmar Knoblauch

  • Alexander I. Spira

Medical Centers

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Chungbuk National University Hospital, Cheongju, Korea

  • Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

  • Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of (South), Korea

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • New York University School of Medicine, New York, NY

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • Karmanos Cancer Institute, Detroit, MI

  • University of California, Irvine, Fullerton, CA

  • Drug Development Unit, The Royal Marsden and Institute of Cancer Research, Sutton, UK

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Janssen, Spring House, PA

  • US Oncology Research/Virginia Cancer Specialists, Fairfax, VA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

  • Circulating DNA

Drug/Treatment

  • Tagrisso

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • NCT02609776

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved